Form 4: INSMED Chief People Strategy Officer Exercises Options and Sells Shares Under Pre-Arranged Plans

INSMED Inc.'s Chief People Strategy Officer, S. Nicole Schaeffer, executed significant stock option exercises and subsequent share sales totaling over 100,000 shares in early June 2025, all conducted under pre-established 10b5-1 trading plans.

Summary

• S. Nicole Schaeffer, Chief People Strategy Officer of INSMED Inc. (INSM), engaged in multiple transactions involving the company's common stock on June 10 and June 11, 2025.
• On June 10, 2025, Ms. Schaeffer exercised stock options to acquire 38,300 shares of common stock at an exercise price of $17.16 per share.
• Immediately following the option exercise on June 10, 2025, she sold 38,300 shares of common stock at a price of $88.64 per share.
• On June 11, 2025, Ms. Schaeffer exercised additional stock options to acquire 70,000 shares of common stock at an exercise price of $13.91 per share.
• Also on June 11, 2025, she sold a total of 99,172 shares of common stock across multiple transactions at weighted average prices ranging from $91.68 to $96.02 per share.
• All reported transactions were executed pursuant to Rule 10b5-1 trading plans adopted on August 15, 2024, and February 26, 2025.
• Following these transactions, Ms. Schaeffer's direct beneficial ownership of INSMED common stock stands at 89,407 shares, and she holds 87,290 exercisable stock options.
• The options exercised on June 10, 2025, had an exercise price of $17.16 and an expiration date of May 17, 2027.
• The options exercised on June 11, 2025, had an exercise price of $13.91 and an expiration date of January 3, 2029.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While insider selling can sometimes be a negative signal, the fact that these transactions were conducted under pre-arranged 10b5-1 plans mitigates any immediate negative interpretation. The significant profit realized by the executive from option exercises is a positive for the individual.

Positives

• The transactions were conducted under Rule 10b5-1 trading plans, indicating pre-scheduled sales rather than reactive selling based on immediate company news.
• The significant difference between the option exercise prices ($17.16 and $13.91) and the sale prices (ranging from $88.64 to $96.02) indicates substantial profitability for the insider on these transactions.

Negatives

• The net effect of the transactions was a reduction in the direct beneficial ownership of common stock by a key executive, which can sometimes be perceived negatively by investors, even if pre-planned.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing is a routine insider transaction report and does not provide information directly related to broader industry trends or competitive landscape. It reflects an individual executive's pre-planned stock transactions.

Stakeholder Impact

• Shareholders: May view the insider selling with slight caution, but the pre-planned nature via 10b5-1 plans reduces concerns about immediate negative company prospects. The executive's continued significant holdings (both direct and derivative) suggest ongoing alignment of interests.
• Employees: No direct impact mentioned.

Key Dates

Keywords

INSMED Inc., INSM, SEC Form 4, Insider Trading, Stock Options, Beneficial Ownership, 10b5-1 Plan, Executive Compensation, Share Sale